Our commitment to advance global health: open access to our BEPO™ technology platform for humanitarian programs
As a company dedicated to global health, we believe that the most important innovations are those that benefit everyone, everywhere, regardless of economic or strategic considerations. In keeping with the initial mission of the pharmaceutical industry, we also believe that access to healthcare is a basic human right. This is why we give equal importance to our for-profit activities and our humanitarian programs, each of which is fully part of MedinCell’s strategic objectives.
Because it can be a powerful tool for humanitarian campaigns, we are committed to giving free access to our BEPO™ technology to ensure that effective treatments reach as many patients as possible.
We are interacting with leading research institutes and global health foundations/NGOs to explore the use and the benefits of the BEPO™ technology through specific nonprofit programs addressing critical issues such as HIV, infectious diseases or birth control.
Illustration: BEPO™ against river blindness
Onchocerciasis – also known as river blindness – is a disease caused by infection by the parasitic worm Onchocerca volvulus. Symptoms include severe itching, bumps under the skin, and blindness. It is one of the major causes of blindness due to infection. The parasitic worm is spread by the bites of a black fly living near rivers, hence the name of the disease. Within the human body, the adult female worm (macrofilaria) produces thousands of baby or larval worms (microfilariae) which migrate in the skin and the eye. According to the World Health Organization (WHO) at least 25 million people are infected worldwide; of these people, 300,000 are blind and 800,000 have some sort of visual impairment. Some 123 million people are at risk of becoming infected with the parasite. Visit WHO website for further information
Current treatment for onchocerciasis
There is no vaccine against river blindness and the only prevention is to avoid being bitten by flies. Treatments, such as Ivermectin, are available to kill the larvae in the body and thus prevent the symptoms of the disease. Most current treatments kill the larvae but not the adult worms, which does not really help to eradicate the disease.
The BEPO™ strategy to fight river blindness
Studies show that high repetitive doses of Ivermectin induce female worm death. Our hypothesis is that by maintaining Ivermectin concentration thanks to a BEPO™ 12-month acting formulation, we should also induce adult female worm death.
We are currently carrying out a study with specialized research institute partners in Africa to validate our hypothesis on contaminated cattle.
Other illustration of current humanitarian projects
- BEPO™ against Malaria
- BEPO™ technology applied to contraception
- BEPO™ to prevent AIDS
For further information or any request: email@example.com